Other types of cancer screening

Finland has participated in a European joint study that found PSA-based screening reduces the deaths from prostate cancer by a fifth (4. Schröder et al., 2014). Despite this, prostate screening is still not recommended in any European country due to the disadvantages it has caused, including considerable overdiagnosis and overtreatment.

Screening of smokers using low dose computed tomography has cut lung cancer mortality by a fifth (5. van der Aalst et.al., 2016). However, such screening is not being recommended for the time being due to the unnecessary follow-up measures brought about. The screening of lung cancer is being studied through renewed testing methods in the Netherlands and other countries.
An extensive screening for ovarian cancer screening is currently underway and the mortality estimates will be completed in the next few years (6. Jacobs et al 2016). Stomach cancer screening has been studied in countries with high incidence of this cancer (7. Ford et al., 2014). In countries with a low rate of stomach cancer such as Finland, screening is not considered necessary.

References

  1. Malila N, Anttila A, Hakama M. Colorectal cancer screening in Finland: details of the national screening programme implemented in Autumn 2004. J Med Screen 2005; 12: 28–32.
  2. Pitkäniemi J, Seppä K, Hakama M ym. Effectiveness of screening for colorectal cancer with a faecal occult-blood test, in Finland. BMJ Open Gastro 2015; 2: e000034.
  3. European Colorectal Cancer Screening Guidelines Working Group. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013; 45: 51-9.
  4. Schröder F, Hugosson J, Roobol MJ ym. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384(9959): 2027–35.
  5. van der Aalst C, ten Haaf K, de Koning H. Lung cancer screening: latest developments and unanswered questions. Lancet Respir Med 2016; 4: 749-61.
  6. Jacobs IJ, Menon U, Ryan A ym. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomized controlled trial. Lancet 2016; 387(10022): 945–56.
  7. Ford A, Fordman D, Hunt RH ym. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic individuals: systematic review and meta-analysis of randomized controlled trials. BMJ 2014; 348: g3174.